SUZUKEN CO.,LTD.
9987・Prime Market・Wholesale Trade
Business
Suzuken Co., Ltd. was founded in 1932 and is one of the largest pharmaceutical wholesalers in Japan. Its core business is the nationwide wholesale distribution of prescription drugs, diagnostic reagents, and medical devices, forming a group with 38 subsidiaries and 10 affiliated companies. Its business scope extends beyond pharmaceutical wholesaling to include research, development, and manufacturing of prescription drugs and medical devices (Sanwa Kagaku Kenkyusho Co., Ltd., Kenz Medico Co., Ltd.), insurance-covered pharmacies and nursing care services (Uni Smile Co., Ltd. and others), outsourced distribution of specialty pharmaceuticals such as treatments for rare diseases (SD Collabo Co., Ltd.), and outsourced logistics for pharmaceutical manufacturers and digital health services (Chuo Unyu Co., Ltd., Collabo Square Co., Ltd. and others). Its principal customers are approximately 160,000 medical institutions, insurance pharmacies, and pharmaceutical manufacturers nationwide. Consolidated net sales for FY2026 (ending March 2026) totaled ¥2,486,647 million.
Business Model
Core earnings are generated from the purchase-and-sale margin (margin business) of the pharmaceutical wholesale business. In addition, the specialty pharmaceutical distribution outsourcing business earns fees by taking on distribution management functions outsourced by pharmaceutical manufacturers. The medical-related services and other business diversifies revenue through manufacturer logistics outsourcing for pharmaceutical companies and digital health services. The company is also building new information- and digital-based revenue models, such as nationwide expansion of the Qubix system and marketing support leveraging IDs of over 440,000 medical and nursing care professionals.
Company Strengths
In the pharmaceutical wholesale business, the company has built trading relationships with approximately 160,000 customers nationwide through 156 branches. This wide-area sales network is an asset with high barriers to entry, formed over many years of mergers and integrations (with Kato Yakuhin, Akiyama Aiseikan, and others), and also functions as a platform for specialty pharmaceutical distribution outsourcing and digital health service deployment.
The specialty pharmaceutical traceability system "Cubix" (Cubics), based on an exclusive licensing agreement with Cencora Inc. of the US, was operating with 710 units installed at 597 sites nationwide as of fiscal year-end. It has been introduced at more than half of designated cancer care hospitals and about 80% of national university hospitals. This infrastructure, which is difficult for competitors to replicate, directly contributes to securing sole distribution outsourcing contracts for treatments such as rare disease drugs.
In April 2024, the company began full operation of a metropolitan area distribution center in Soka City, Saitama Prefecture, based on an industry-first concept. It achieves automation and labor savings through the latest robotics technology, and the wholesale logistics hub is equipped with adjacent areas for contract manufacturing operations and manufacturer logistics. Of the total capital investment of ¥19,510 million, ¥14,008 million was allocated to the distribution center, giving the company a logistics infrastructure that simultaneously achieves reduced transportation costs, GDP quality compliance, and enhanced BCP (business continuity planning).
ENVALITH's Perspective
Performance Trend
Revenue increased for five consecutive fiscal periods, rising from ¥2,232,774 million in FY2022 (ended March 2022) to ¥2,486,647 million in FY2026 (ending March 2026), up 11.3% over the period. Operating profit improved sharply from ¥13,777 million in FY2022 (ended March 2022) to ¥37,125 million in FY2025 (ended March 2025), but declined for the first time in FY2026 (ending March 2026) to ¥36,374 million (down 2.0% year on year). As an external factor, growth in the prescription drug market (new drugs in anticancer agents and specialty pharmaceuticals) contributed to higher revenue, while rising procurement prices, logistics costs, and outsourcing expenses pressured operating profit. Profit attributable to owners of parent increased to ¥38,136 million (up 10.6% year on year), reflecting the recognition of a ¥15,581 million gain on sales of policy-holding (cross-shareholding) stocks. For FY2027 (ending March 2027), the company forecasts operating profit of ¥31,200 million (down 14.2% year on year) and net profit of ¥25,000 million (down 34.4% year on year), a significant decline attributable to the absence of the prior year's extraordinary gain and upfront investment spending.
Growth Strategy
Aiming to become a health-creating business group centered on three pillars: evolution into a next-generation wholesaler, redesign of the business portfolio, and strengthening of the management foundation
Expanded the specialty pharmaceutical traceability system "Cubix" to 597 facilities and 710 units in operation nationwide (covering more than half of designated cancer care hospitals and approximately 80% of national university hospitals). Through collaboration with peripheral services and enhanced functionality, the company is expanding into visualization of distribution inventory and demand forecasting, continuing to strengthen the acquisition of outsourcing contracts from pharmaceutical companies.
The "Metropolitan Area Logistics Center" in Soka City, Saitama Prefecture, became fully operational in April 2024. In May 2025, the company completed acquisition of land in Kasugai City, Aichi Prefecture for the "Chubu Regional Logistics Center (tentative name)," with construction scheduled to begin in October 2027. Centered on these two facilities, the company aims to achieve automation of its logistics network, reduced transportation and distribution costs, compliance with GDP standards, and strengthened BCP (business continuity planning).
In February 2026, the company made "medimo," a generative AI-powered SaaS for medical documentation, a wholly owned subsidiary (cumulative adoption at over 1,000 facilities nationwide). In April 2026, Embrace Co., Ltd. and Collabo Square Co., Ltd. will be integrated, accelerating the creation of new information-based revenue businesses such as marketing support utilizing over 440,000 registered medical and nursing care professional IDs.
Built around three pillars—"evolution into a next-generation wholesaler," "redesign of the business portfolio," and "strengthening of the management foundation"—the plan targets consolidated net sales of ¥2.7 trillion or more, ROE of 7.0% or higher, and an ordinary income margin of 1.5% or higher by FY2029 (ending March 2029). The company plans cumulative investment of ¥60 billion or more over the three-year period, with a long-term goal of net sales of ¥3 trillion or more and ROE of 8.0% or higher by FY2031 (ending March 2031).
In FY2026 (ending March 2026), the company reduced cross-shareholdings in 11 consolidated issues, recording a gain on sale of investment securities of ¥15,581 million. The company has set a goal to reduce cross-shareholdings to 10% or less of consolidated net assets by FY2029 (ending March 2029). The dividend is planned at ¥120 per share for FY2027 (ending March 2027), a 20% increase, with a policy of continuing shareholder returns based on a total payout ratio of 100%.
Last updated: July 19, 2026